ClinicalTrials.gg
WithdrawnNCT00986778Updated Sep 1, 2015

Entecavir Plus Adefovir in Lamivudine-Resistant Patients

A Phase 4 interventional study of Lamivudine and Entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Withdrawn. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-09-01.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Business Objectives Changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
60th of 61
0 · median 109
Started
2009
with 2 others
Phase 4
33 of 64
2 open now
Registered
22nd of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 60th largest by enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2009, is one of 33 in phase 4, and was the 22nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in Chinese adults with lamivudine-resistant chronic hepatitis B infection

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CHB HBeAg(+) Subject with Lamivudine treatment history must have LVDr substitution at rtM204V/I
  • Naïve to nucleoside/nucleotide analogues except for LVD
  • > 17,200 IU/mL
  • Compensated liver function
  • Serum \<10 ×

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Evidence of decompensated cirrhosis
  • Coinfection with , virus (HCV), or hepatitis D virus (HDV)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Lamivudine plus Adefovir

    Drug: Lamivudine · Drug: Adefovir

  • Active comparator
    Entecavir

    Drug: Entecavir

  • Experimental
    Entecavir plus Adefovir

    Drug: Entecavir · Drug: Adefovir

Interventions

  • Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response

    Also known as: Heptotin

  • Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response

    Also known as: Baraclude

  • Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response

    Also known as: Hepsera

06

What researchers measure

Primary outcomes

  1. The proportion of patients with HBV DNA < 50 IU/mL at W48

    Time frame: Week 48

Secondary outcomes

  1. The proportion of patient with HBV DNA < 50 IU/mL at W 96

    Time frame: Week 96

  2. Mean reduction of HBV DNA at W 48 & 96

    Time frame: Week 48 and 96

  3. The proportion of subjects with ALT normalization at W 48 & 96

    Time frame: Week 48 & Week 96

  4. The proportion of subjects achieved HBeAg loss, seroconversion, HBsAg loss and seroconversion at W48 & 96

    Time frame: Week 48 & 96

  5. Safety

    Time frame: Week 48 and Week 96

  6. Resistance

    Time frame: Week 48 & Week 96

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Dec 2012 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2009
First posted
Sep 30, 2009
Start
Dec 2009
Primary completionEst.
Dec 2012
CompletionEst.
Jun 2014
Last update
Sep 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00986778
First posted
Sep 30, 2009
Start date
Dec 2009
Primary completion
Dec 2012 (estimated)
Completion
Jun 2014 (estimated)
Last update
Sep 1, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Adefovir

Start the discussion